首页|期刊导航|浙江大学学报(医学版)|类端粒沉默干扰体1通过p38 MAPK/线粒体动力学稳态轴调控神经元淀粉样前体蛋白表达

类端粒沉默干扰体1通过p38 MAPK/线粒体动力学稳态轴调控神经元淀粉样前体蛋白表达OA

DOT1L controls neuronal amyloid precursor protein expres-sion via the p38 MAPK-mediated mitochondrial dynamics homeostasis axis

中文摘要英文摘要

目的:明确表观遗传调节因子类端粒沉默干扰体1(DOT1L)及其介导的组蛋白H3第79位赖氨酸(H3K79)甲基化修饰对神经元淀粉样前体蛋白(APP)表达的调控作用,并阐明线粒体动力学稳态及其上游p38丝裂原激活的蛋白激酶(p38 MAPK)在该调控过程中的核心机制.方法:采用APP/早老蛋白1(PS1)双转基因小鼠模型及过表达人源瑞典突变型APP的神经母细胞瘤细胞(N2a-APPswe细胞)模拟AD.通过免疫荧光染色法检测小鼠脑组织中DOT1L的表达和定位.利用DOT1L特异性抑制剂EPZ5676处理N2a-APPswe细胞,分别设置空白对照组、溶剂对照组、DOT1L抑制剂组及DOT1L抑制剂+p38激动剂(绞股蓝提取物)组.采用蛋白质印迹法检测线粒体分裂关键蛋白质DRP1的Ser616和Ser637位点磷酸化水平、自噬相关蛋白质p62水平和LC3-Ⅱ/LC3-Ⅰ比值、信号分子p38磷酸化水平以及APP代谢相关蛋白质APP、BACE1和PS1的表达水平;采用逆转录定量聚合酶链反应检测APP、线粒体分裂及融合相关基因的表达;基于蛋白质组学数据,通过基因本体分析、WikiPathways富集分析及STRING蛋白质-蛋白质相互作用网络筛选关键信号通路;采用Mito-Tracker荧光染色法检测线粒体分支长度.结果:与野生型小鼠比较,APP/PS1小鼠神经元中DOT1L表达减少.抑制DOT1L后,H3K79二甲基化水平降低(P<0.01),APP表达水平升高但其mRNA表达水平下降(均P<0.01).差异表达蛋白质高度富集于线粒体电子传递链.与溶剂对照组比较,DOT1L抑制剂组线粒体分裂受到抑制,表现为磷酸化DRP1(Ser616)水平下降、磷酸化DRP1(Ser637)水平升高、MIEF1 mRNA表达水平下降、MFN1 mRNA表达水平升高(均P<0.05),线粒体平均分支长度增加(P<0.05),并伴随p38 MAPK磷酸化水平下降(P<0.05).与DOT1L抑制剂组比较,加用p38激动剂可显著逆转上述线粒体动力学异常(均P<0.05),并下调APP、BACE1和PS1的异常高表达(均P<0.05).结论:DOT1L通过调控p38 MAPK介导的信号通路维持线粒体正常分裂及功能稳态,进而调控APP表达.

Objective:To investigate the regulatory role of epigenetic regulator disruptor of telomeric silencing 1-like(DOT1L)and its mediated histone H3 lysine 79(H3K79)methylation in modulating neuronal amyloid precursor protein(APP)expression,and to elucidate the underlying mechanisms involving mitochondrial dynamics homeo-stasis and the upstream p38 mitogen-activated protein kinase(p38 MAPK).Methods:Alzheimer's disease(AD)models were established using APP/presenilin-1(APP/PS1)double-transgenic mice and N2a cells overexpressing the human Swedish mutant APP(N2a-APPswe).Immunofluorescence staining was employed to assess DOT1L expression and localization in mouse brain tissues.N2a-APPswe cells were treated with the DOT1L-specific inhibitor EPZ5676 and divided into four groups:blank control,solvent control,DOT1L inhibitor,and DOT1L inhibitor plus p38 agonist(Gynostemma pentaphyllum extract).Western blotting was performed to measure the phosphorylation levels of DRP1 at Ser616 and Ser637,the levels of autophagy-related proteins p62 and the LC3-Ⅱ/LC3-Ⅰ ratio,the phosphorylation level of p38 MAPK,as well as the expression of APP and APP-processing proteins BACE1 and PS1.Reverse transcription quantitative polymerase chain reaction was used to detect mRNA levels of APP and genes involved in mitochondrial fission and fusion.Proteomics data were systematically analyzed through Gene Ontology analysis,WikiPathways enrichment analysis,and STRING protein-protein interaction network analysis to identify key signaling pathways.Mitochondrial network morphology was evaluated by Mito-Tracker fluorescence staining to measure average branch length.Results:DOT1L expression was significantly reduced in neurons of APP/PS1 mice compared to wild-type controls.DOT1L inhibition led to decreased H3K79 dimethylation levels(P<0.01),accompanied by a marked increase in APP protein expression(P<0.01),although APP mRNA levels were reduced(P<0.01).Proteomics analysis revealed that differentially expressed proteins were highly enriched in the mitochondrial electron transport chain.Compared with the solvent control,the DOT1L inhibitor group showed inhibited mitochondrial fission,as evidenced by decreased p-DRP1(Ser616),increased p-DRP1(Ser637),downregulated MIEF1 mRNA,upregu-lated MFN1 mRNA(all P<0.05),and increased average mitochondrial branch length(P<0.05),along with reduced phosphorylation level of p38 MAPK(P<0.05).Co-administration of the p38 agonist significantly reversed these mitochondrial dynamics abnormalities(all P<0.05)and attenuated the abnormally elevated protein levels of APP,BACE1,and PS1(all P<0.05)compared to the DOT1L inhibitor group.Conclusion:DOT1L maintains normal mitochondrial fission and functional homeostasis through regulation of the p38 MAPK mediated signaling pathway,thereby modulating APP expression.

张玉珉;朱飞宇;吴啸天;李占松;黄鹏;高延盼;曾玲晖

浙大城市学院医学院 浙江省神经损伤修复新靶点与药物研究重点实验室,浙江 杭州 310015浙大城市学院医学院 浙江省神经损伤修复新靶点与药物研究重点实验室,浙江 杭州 310015浙大城市学院医学院 浙江省神经损伤修复新靶点与药物研究重点实验室,浙江 杭州 310015浙大城市学院医学院 浙江省神经损伤修复新靶点与药物研究重点实验室,浙江 杭州 310015浙大城市学院医学院 浙江省神经损伤修复新靶点与药物研究重点实验室,浙江 杭州 310015浙大城市学院医学院 浙江省神经损伤修复新靶点与药物研究重点实验室,浙江 杭州 310015浙大城市学院医学院 浙江省神经损伤修复新靶点与药物研究重点实验室,浙江 杭州 310015

医药卫生

阿尔茨海默病β淀粉样蛋白淀粉样前体蛋白表观遗传调控类端粒沉默干扰体1线粒体融合线粒体分裂p38丝裂原激活的蛋白激酶

Alzheimer's diseaseAmyloid β-proteinAmyloid precursor proteinEpigenetic regulationDisruptor of telomeric silencing 1-likeMitochondrial fusionMitochondrial fissionp38 mitogen-activated protein kinase

《浙江大学学报(医学版)》 2026 (5)

391-403,13

浙江省自然科学基金(LTGD24H090003)浙江省大学生创新训练项目(S202513021060)浙大城市学院大学生创新训练项目(X202401137)This study was supported by Zhejiang Provincial Natural Science Foundation of China(LTGD24H090003),Zhejiang Province University Students'Innovation and Entrepreneurship Training Program(S202513021060),and Hangzhou City University Students'Innovation and Entrepre-neurship Training Program(X202401137).

10.3724/zdxbyxb-2025-0706

评论